Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
ENDPOINTS NEWS22h
Lil­ly’s ear­ly blad­der can­cer da­ta hint at safe­ty edge over J&J’s Balver­sa
Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...